Anie Philip
PhD, MSc
- President, Skin Research Group of Canada (2019-2021) (https://www.skinresearchgroup.org/)
- Associate Director, Skin Investigator’s Network (SkIN) Canada (2020-2024) (https://skincanada.org/)
- Executive Committee Member, Skin Investigator’s Network (SkIN) Canada (2020-2024)
- Panel Member, CIHR Cell Biology B Committee (2020-2023)
- Board of Directors, Wound Healing Society USA (2016-2019)
The Research Topics are indicated below: For a short description of the projects please see the link below:
- Skin and Lung Fibrosis
- Squamous cell carcinoma
- Cartilage Repair/Osteoarthritis
- Estrogen-related receptors
https://www.mcgill.ca/skinandcartilage/
https://www.mcgill.ca/expmed/dr-anie-philip
https://www.mcgill.ca/experimentalsurgery/supervisionfaculty/philip
Scleroderma, squamous cell carcinoma, osteoarthritis, wound healing, nuclear receptors in reproduction and cancer
Anie Philip (PhD) is a full professor at McGill University and a Senior Scientist at the Research Institute of the McGill University Health Center (RI-MUHC). She is currently the President of ‘Skin Research Group of Canada’. Dr Philip is also the Associate Director of the ‘Skin Investigators Network of Canada (SkIN Canada)’. Her most significant contributions include the discovery of CD109 as a TGF-b co-receptor and inhibitor of tissue fibrosis, and the finding that CD109 is a promoter of tumorigenesis in squamous cell carcinoma. Her laboratory is supported by three CIHR Project Grants, a CIHR Network grant, and an NSERC Discovery grant. She has been funded by other agencies including the Department of Defense (DOD), Heart and Stroke Foundation, and Canadian Arthritis Network. Dr Philip collaborates with scientists at the National and International levels and holds grants as a co-applicant with them (New Frontiers in Research fund, Canada, FRQS). Her laboratory has an excellent track record in the training of HQP and typically supervises as the primary supervisor 2-3 PhD students, 2-3 MSc students, 2 PDFs and 2 undergraduates/medical students.
1. Zhou S, Tabaries S, Siegel P, Philip A: CD109 drives tumorigenesis and metastasis by modulating EGFR/AKT signaling in squamous cell carcinoma. British journal of cancer 2021, in revision.
2. Ghanbari F, Park M, Philip A: Cholesterol-induced metabolic reprogramming in breast cancer cells is mediated via ERRa pathway. Cancers 2021, 13(11):2605. https://pubmed.ncbi.nlm.nih.gov/34073320
3. Ghanbari F, Mader S, Philip A: Cholesterol as an endogenous ligand of ERRa promotes ERRa-mediated cellular proliferation and metabolic target gene expression in breast cancer cells. Cells 2020, 9(8):1765. https://pubmed.ncbi.nlm.nih.gov/32717915
4. Zhou S, da Silva SD, Siegel PM, Philip A: CD109 acts as a gatekeeper of the epithelial trait by suppressing epithelial to mesenchymal transition in squamous cell carcinoma cells in vitro. Scientific reports 2019, 9(1):16317. https://pubmed.ncbi.nlm.nih.gov/31695056
5. Istomine R, Alvarez F, Almadani Y, Philip A, Piccirillo CA: The deubiquitinating enzyme ubiquitin-specific peptidase 11 potentiates TGF-b signaling in CD4(+) T Cells to facilitate Foxp3(+) regulatory T and TH17 cell differentiation. J Immunol 2019, 203(9):2388-2400. https://pubmed.ncbi.nlm.nih.gov/31554694
6. Ghanbari F, Hebert-Losier A, Barry J, Poirier D, Giguere V, Mader S, Philip A: Isolation and functional characterization of a novel endogenous inverse agonist of estrogen related receptors (ERRs) from human pregnancy urine. The Journal of steroid biochemistry and molecular biology 2019, 191:105352. https://pubmed.ncbi.nlm.nih.gov/30954508
7. Finnson KW, Almadani Y, Philip A: Non-canonical (non-SMAD2/3) TGF-b signaling in fibrosis: mechanisms and targets. Semin Cell Dev Biol 2019, 101:115-122. https://pubmed.ncbi.nlm.nih.gov/31883994
8. Alzahrani A, Chi Y, Finnson KW, Blati M, Lussier B, Kapoor M, Roy S, Philip A: Endoglin haploinsufficiency is associated with differential regulation of extracellular matrix production during skin fibrosis and cartilage repair in mice. J Cell Commun Signal 2018, 12(1):379-388. https://pubmed.ncbi.nlm.nih.gov/29488175
9. Zhou S, Cecere R, Philip A: CD109 released from human bone marrow mesenchymal stem cells attenuates TGF-b-induced epithelial to mesenchymal transition and stemness of squamous cell carcinoma. Oncotarget 2017, 8(56):95632-95647. https://pubmed.ncbi.nlm.nih.gov/29221155
10. Vorstenbosch J, Nguyen CM, Zhou S, Seo YJ, Siblini A, Finnson KW, Bizet AA, Tran SD, Philip A: Overexpression of CD109 in the epidermis differentially regulates ALK1 versus ALK5 signaling and modulates extracellular matrix synthesis in the skin. The Journal of investigative dermatology 2017, 137(3):641-649. https://pubmed.ncbi.nlm.nih.gov/27866969
11. Li C, Hancock M, Sehgal PB, Zhou S, Reinhardt D, Philip A: Soluble CD109 binds TGF-b and antagonizes TGF-b signaling and responses. Biochemical Journal 2016, 473(5):537-547. https://pubmed.ncbi.nlm.nih.gov/26621871
12. Denis JF, Sader F, Gatien S, Villiard E, Philip A, Roy S: Activation of Smad2 but not Smad3 is required for mediating TGF-b signaling during limb regeneration in axolotls. Development 2016, 143(19):3481-3490. https://pubmed.ncbi.nlm.nih.gov/27549395
13. Winocour S, Vorstenbosch J, Trzeciak A, Lessard L, Philip A: CD109, a novel TGF-b antagonist, decreases fibrotic responses in a hypoxic wound model. Exp Dermatol 2014, 23(7):475-479. https://pubmed.ncbi.nlm.nih.gov/24815824
14. Vorstenbosch J, Gallant-Behm C, Trzeciak A, Roy S, Mustoe T, Philip A: Transgenic mice overexpressing CD109 in the epidermis display decreased inflammation and granulation tissue and improved collagen architecture during wound healing. Wound Repair Regen 2013, 21(2):235-246. https://pubmed.ncbi.nlm.nih.gov/23438099
15. Vorstenbosch J, Al-Ajmi H, Winocour S, Trzeciak A, Lessard L, Philip A: CD109 overexpression ameliorates skin fibrosis in mouse model of bleomycin-induced scleroderma. Arthritis and rheumatism 2013, 65(5):1378-1383. https://pubmed.ncbi.nlm.nih.gov/23436317
16. Sinno H, Malhotra M, Lutfy J, Jardin B, Winocour S, Brimo F, Beckman L, Watters K, Philip A, Williams B et al: Complements c3 and c5 individually and in combination increase early wound strength in a rat model of experimental wound healing. Plast Surg Int 2013, 2013:243853. https://pubmed.ncbi.nlm.nih.gov/23766899
17. Sinno H, Malholtra M, Lutfy J, Jardin B, Winocour S, Brimo F, Beckman L, Watters K, Philip A, Williams B et al: Topical application of complement C3 in collagen formulation increases early wound healing. J Dermatolog Treat 2013, 24(2):141-147. https://pubmed.ncbi.nlm.nih.gov/22007700
18. Finnson K, McLean S, Di Guglielmo GM, Philip A: Dynamics of transforming growth factor-b signaling in wound healing and scarring. Advances in wound care 2013, 2(5):195-214. https://pubmed.ncbi.nlm.nih.gov/24527343
19. Finnson K, Arany P, Philip A: Transforming growth factor-b signaling in cutaneous wound healing: lessons learned from animal studies. Advances in wound care 2013, 2(5):225-237. https://pubmed.ncbi.nlm.nih.gov/24761336